Dr CHIU Ka Fung Peter    
趙家鋒

Associate Professor
MBChB (CUHK), FRCSEd (Urol), FCSHK, FHKAM (Surg)

Urology
(852) 3505 2625
peterchiu@surgery.cuhk.edu.hk
AAY-2052-2020
0000-0002-1499-8372

Biography

Dr Peter Chiu is currently an Associate Professor of the Chinese University of Hong Kong. He has primary interests in prostatic diseases including prostate cancer and benign prostatic hyperplasia. For prostate cancer, he has conducted studies in novel diagnostic modalities including blood biomarker prostate health index (phi) and urine biomarker spermine. He is leading a study on the role of MRI imaging and biomarkers in optimizing prostate cancer screening in Chinese men.  He is also involved in the initiation of focal therapy service (e.g. HIFU) for prostate cancer in Hong Kong, and is the principle investigator of a phase 2 clinical trial on microwave focal therapy for prostate cancer. For treatment of benign prostatic hyperplasia, he has conducted research in prostate artery embolization (PAE) and photoselective vaporization of prostate (PVP).

Peter has received numerous research funding and has published more than 50 articles in peer-reviewed journals including European Urology and BJU International. He has been a reviewer for multiple international journals. He is currently the associate editor of the online learning platform Grand Rounds in Urology, and he has been heavily involved in training of Urology trainees in Hong Kong since 2017 and was the chairman of Younger Urologists’. He is currently the honorary secretary of the Hong Kong Urological Association (HKUA).

Research Interests

• Blood and urine biomarkers for prostate cancer
• Prostate cancer screening
• MRI-guided prostate biopsies
• Focal therapy for prostate cancer
• Advanced robotic surgery for urological cancers
• Novel treatment for benign prostatic hyperplasia
• Microsurgery under advanced imaging for varicocele treatment

Additional Information

• Honorary Secretary, Hong Kong Urological Association
• Associate Editor, Grand Rounds in Urology
• Council member, Societe Internationale D'Urologie (SIU) Academy Education Council

Selected Publications

1. Chiu PK, Ng CF, Semjonow A, Zhu Y, Vincendeau S, Houlgatte A, Lazzeri M, Guazzoni G, Stephan C, Haese A, Bruijne I, Teoh JY, Leung CH, Casale P, Chiang CH, Tan LG, Chiong E, Huang CY, Wu HC, Nieboer D, Ye DW, Bangma CH, Roobol MJ. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. Eur Urol. 2019 Apr;75(4):558-561.
2. Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, Tijsterman JD, Beerlage HP, Mannaerts CK, Schimmöller L, Albers P, Arsov C. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. Eur Urol. 2019 Feb;75(2):310-318.
3. Ng CF, Teoh JY, Chiu PK, Yee CH, Chan CK, Hou SS, Kaouk J, Chan ES. Robot-assisted single-port radical prostatectomy: A phase 1 clinical study. Int J Urol. 2019 Sep;26(9):878-883.
4. Chiu PK, Alberts AR, Venderbos LDF, Bangma CH, Roobol MJ. Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. BJU Int. 2017 Sep;120(3):394-400.
5. Chiu PK, Roobol MJ, Nieboer D, Teoh JY, Yuen SK, Hou SM, Yiu MK, Ng CF. Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population. Prostate Cancer Prostatic Dis. 2017 Mar;20(1):99-104.
6. Chiu PK, Teoh JY, Lee WM, Yee CH, Chan ES, Hou SM, Ng CF. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination. Investig Clin Urol. 2016 Sep;57(5):336-42.
7. Chiu PK, Roobol MJ, Teoh JY, Lee WM, Yip SY, Hou SM, Bangma CH, Ng CF. Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume. Int Urol Nephrol. 2016 Oct;48(10):1631-7.
8. Teoh JY, Chiu PK, Yee CH, Wong HM, Chan CK, Chan ES, Hou SS, Ng CF. Prostatic artery embolization in treating benign prostatic hyperplasia: a systematic review. Int Urol Nephrol. 2017 Feb;49(2):197-203.